Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - interferon beta-1b - sklerosi multipla - immunostimulanti, - extavia huwa indikat għall-kura ta': pazjenti b'avveniment wieħed demyelinating bi proċess infjammatorju attiv, jekk ikun sever biżżejjed li jkun jeħtieġ il-kura b'kortikosterojdi ġol-vina, jekk dijanjosi alternattivi kienu esklużi, u jekk kien stabbilit li huma f'riskju għoli li jiżviluppaw sklerożi multipla klinikament definita;pazjenti bi sklerożi multipla li tirkadi u tbatti l-isklerożi multipla u żewġ jew aktar attakki reċidivi fi żmien l-aħħar sentejn;il-pazjenti bi sklerożi multipla progressiva sekondarja bil-marda attiva, evidenzjata mill-irkadar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie ltd - dasabuvir sodium - epatite Ċ, kronika - antivirali għal użu sistemiku - exviera huwa indikat flimkien ma 'prodotti mediċinali oħra għall-kura ta' l-epatite Ċ kronika (chc) fl-adulti. għall-vajrus tal-epatite Ċ (hcv) ġenotip attività speċifika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - agalsidase beta - marda ta 'fabry - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - fabrazyme huwa indikat għal terapija ta 'sostituzzjoni ta' enzimi fit-tul f'pazjenti b'dijanjosi kkonfermata ta 'marda ta' fabry (defiċjenza ta 'α-galaktosidase-a).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - l-osteoporożi, il-menopawża - drogi għat-trattament ta 'mard tal-għadam - trattament ta 'osteoporożi ta' wara l-menopawsa f'pazjenti f'riskju ta 'insuffiċjenza ta' vitamina-d. fosavance inaqqas ir-riskju ta'ksur vertebrali u tal-ġenbejn.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda pharma a/s - metformin hydrochloride, pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - glubrava huwa indikat bħala kura tat-tieni linja ta 'pazjenti adulti tat-tip-2-diabetes-mellitus, speċjalment pazjenti b'piż żejjed, li ma jistgħux jiksbu kontroll glikimiku suffiċjenti bid-doża massima ttollerata ta' metformin orali waħdu. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara tlieta sa sitt xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone jinżamm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - mediċini għall-kura ta'mard fl-għadam, bisphosphonates - sandoz aċidu ibandronic huwa indikat għall-prevenzjoni ta ' l-iskeletru avvenimenti (fratturi patoloġiċi, għadam komplikazzjonijiet li jeħtieġu radjoterapija jew kirurġija) fil-pazjenti bl-metastaΩi tal-kanċer u l-għadma tas-sider.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva pharma b.v. - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - drogi għat-trattament ta 'mard tal-għadam - ibandronic acid 50mgibandronic-aċidu teva huwa indikat għall-prevenzjoni ta ' episodji skeletriċi (fratturi patoloġiċi, komplikazzjonijiet fl-għadam li jeħtieġu r-radjuterapija jew il-kirurġija) f'pazjenti b'kanċer tas-sider u metastażi fl-għadam. ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. tnaqqis fir-riskju ta ' ksur vertebrali ġie muri, l-effikaċja fuq il-ksur fl-għonq tal-femora ma ġietx stabbilita.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaċċini - infanrix hexa huwa indikat għall-vaċċinazzjoni primarja u booster tat-trabi kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u mard ikkawżat minn influwenza Ħemofillika tip-b.